BCL2 and acute myeloid leukemia: To validate the potential clinical relevance of targeting BCL-2 and MCL-1 in TP53-mutant AML mimicking a microenvironment setting in vitro, we co-cultured cells from eight AML patients with TP53 mutations (6/8 had co-mutations, 5/8 were resistant to VEN-based therapy) (Table 1) with MSCs and treated them with VEN, AMG176, or both.